Ocular graft-versus-host disease is an inflammatory eye condition that develops when donated immune cells from a bone marrow or stem cell transplant attack the recipient’s eye tissues, most commonly causing severe dry eye, damaged oil glands in the eyelids, and corneal surface breakdown. It affects a substantial share of transplant survivors: roughly one in five develop it within the first year, and by five years the cumulative rate approaches half of all recipients.1American Journal of Ophthalmology. Evaluation of Incidence, Risk Factors, and Complications of Ocular Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation The condition can range from mild irritation to vision-threatening corneal damage, and managing it often becomes a daily, time-consuming commitment for people already navigating post-transplant recovery.
Who Gets It and When
Ocular GVHD overwhelmingly follows allogeneic hematopoietic stem cell transplantation, the type where a donor’s stem cells replace the patient’s own. The condition tends to appear months after the transplant rather than immediately. One study found the median time from transplant to eye symptoms was about 293 days, with roughly two-thirds of cases surfacing within the first year.2PubMed Central. Onset of Ocular Graft-versus-Host Disease Symptoms after Allogeneic Hematopoietic Stem Cell Transplantation A smaller fraction of patients, around 8% in that cohort, developed eye involvement within the first 100 days. That early onset can catch both patients and transplant teams off guard, since the first months are typically focused on engraftment and systemic recovery rather than eye health.
Cumulative incidence rises steadily over time. Data from a large evaluation showed rates climbing from about 20% at one year to roughly 30% at two years, 41% at three, and nearly 50% by five years after transplant.3American Journal of Ophthalmology. Evaluation of Incidence, Risk Factors, and Complications of Ocular Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation These numbers underscore that ocular GVHD is not a rare complication: it is one of the most common organ-specific manifestations of chronic GVHD overall.
Risk Factors That Raise the Odds
A meta-analysis pooling data across multiple studies identified several factors that increase the likelihood of developing ocular GVHD. Having chronic GVHD in other parts of the body was the strongest predictor, roughly tripling the odds. Oral GVHD and skin GVHD carried particularly high associations, with odds ratios above 5 and above 13, respectively.4PubMed Central. Risk factors for ocular graft-versus-host disease: A systematic review and meta-analysis In practical terms, if you already have GVHD affecting your mouth or skin, the chances of your eyes being hit are substantially elevated.
Other risk factors included receiving peripheral blood stem cells rather than bone marrow (which nearly doubled the odds), having a matched-related donor, having a female donor, prior acute GVHD, and older patient age.5PubMed Central. Risk factors for ocular graft-versus-host disease: A systematic review and meta-analysis Some of these factors are modifiable in transplant planning and some are not, but knowing them helps transplant teams flag higher-risk patients for earlier and more frequent eye screening.
What Happens Inside the Eye
At its core, ocular GVHD is driven by donor T cells that infiltrate the eye’s tissues, particularly the lacrimal glands (which produce the watery layer of tears) and the meibomian glands (which produce the oily layer). The result is a systemic immune attack on the structures responsible for keeping the eye surface lubricated and healthy.6PubMed Central. Meibomian Gland Dysfunction: A Route of Ocular Graft-Versus-Host Disease Progression That Drives a Vicious Cycle of Ocular Surface Inflammatory Damage The meibomian gland damage is particularly insidious because it sets up a self-reinforcing cycle: inflammation destroys gland tissue, the loss of oil destabilizes the tear film, the exposed cornea becomes inflamed, and the inflammation causes further gland damage.
Imaging studies show that patients with ocular GVHD have markedly greater meibomian gland loss compared to healthy people. Interestingly, some gland loss may begin even before transplant, possibly due to the underlying disease being treated or prior chemotherapy and radiation.7Bone Marrow Transplantation. Meibography and meibomian gland measurements in ocular graft-versus-host disease This finding suggests that the transplant process itself adds damage on top of glands that were already compromised, making the eventual dry eye worse than the immune attack alone would explain.
The corneal nerves also take a hit. Patients with chronic ocular GVHD show significantly reduced nerve density in the cornea, and the degree of nerve loss correlates with worse corneal surface damage.8PubMed. The Association between Meibomian Gland Atrophy and Corneal Subbasal Nerve Loss in Patients with Chronic Ocular Graft-versus-host Disease Separately, research using esthesiometry to measure corneal sensation confirmed a strong inverse relationship: the fewer nerves remaining, the worse the corneal staining scores (a measure of surface damage), and the more reduced the corneal sensitivity.9PubMed. Corneal Sensitivity and Neuropathy in Patients With Ocular Graft-Versus-Host Disease This nerve damage creates a paradox for some patients: the cornea is badly damaged but has lost enough feeling that the person does not feel proportionate pain, which can delay reporting symptoms to a doctor.
What It Feels Like
The symptoms most patients notice first are dryness, grittiness, and a burning or stinging sensation that worsens through the day, especially with screen use or in air-conditioned environments. Sensitivity to light is common, and some patients describe the feeling of having sand in their eyes that no amount of blinking resolves. Vision can fluctuate, often improving briefly after blinking or instilling drops and then quickly degrading as the tear film breaks apart again.
Pain is a significant feature for many. When ocular GVHD is complicated by neurotrophic keratopathy, a condition where the damaged corneal nerves paradoxically generate heightened pain signals, patients report higher-intensity eye pain and markedly worse quality of life compared to those with ocular GVHD alone.10PubMed. Ocular pain in ocular graft-versus-host disease patients with neurotrophic keratopathy This type of pain can be especially difficult to treat because it involves nerve dysfunction rather than simple surface irritation, and standard lubricants do little to address it.
How It Is Diagnosed
Diagnosing ocular GVHD requires putting together several clinical findings rather than relying on a single test. An international consensus group proposed a scoring system built on four measurements: a symptom questionnaire (the Ocular Surface Disease Index), a Schirmer test to measure tear production, corneal staining to assess surface damage, and a check for conjunctival redness. Each parameter is scored, and the points are added up to produce a composite score out of 11.11PubMed Central. International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part I)
The diagnosis also takes into account whether the patient has systemic GVHD elsewhere in the body. If systemic GVHD is already confirmed, a composite score of 4 or 5 is classified as “probable” ocular GVHD, and 6 or above is “definite.” Without systemic GVHD, the bar is higher: scores of 6 to 7 are “probable” and 8 or above is “definite.”12Scientific Reports. International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: Proposed Diagnostic Criteria for Chronic GVHD (Part I) This tiered approach recognizes that eye-only GVHD does exist but requires stronger evidence before labeling it as such.
Several other grading scales exist. The NIH eye score uses a 0-to-3 range for dry eye severity. The Japanese dry eye scoring system runs from 0 to 2, incorporating Schirmer values and corneal staining. The DEWS 2007 score uses a broader 0-to-4 scale incorporating nine different parameters.13Scientific Reports. Grading criteria for chronic ocular graft-versus-host disease: Comparing the NIH eye score, Japanese dry eye score and DEWS 2007 score The practical takeaway is that the specific scale your doctor uses matters less than having regular, systematic eye assessments after transplant so changes are caught early.
Tear Biomarkers and What They Cannot Do Yet
Researchers have spent considerable effort trying to find a tear biomarker that could predict ocular GVHD before it develops, which would allow preemptive treatment. Unfortunately, the results so far have been disappointing. A longitudinal study tracking tear cytokines in transplant recipients found that none of the measured inflammatory markers in tears predicted the onset of ocular GVHD. A symptom-based scoring change (the Lee Symptom Scale eye score) did show some association with later development of the condition, but its ability to predict individual cases was low, with a positive predictive value of only about 28%. Its strength was in the negative direction: patients whose symptoms did not change had about a 90% chance of staying free of ocular GVHD.14PubMed Central. Recent advances in ocular graft-versus-host disease For now, routine clinical exams remain more reliable than any laboratory test for catching the disease early.
Treatment Approaches
There is no single cure for ocular GVHD. Treatment is layered, aiming to replace missing tears, reduce inflammation, protect the corneal surface, and in severe cases preserve the structural integrity of the eye. Most patients end up on multiple therapies simultaneously.
Lubricants and Topical Immunosuppressants
Preservative-free artificial tears are the baseline treatment, and most patients with ocular GVHD use them many times a day. For patients with significant inflammation, topical cyclosporine drops are commonly prescribed. When cyclosporine causes burning or intolerance, topical tacrolimus at low concentrations has shown comparable effectiveness. A pilot study comparing the two found that both improved dry eye symptoms and signs to a similar degree, suggesting tacrolimus is a viable alternative for patients who cannot tolerate cyclosporine.15PubMed Central. Treatment of Refractory Dry Eye Associated with Graft Versus Host Disease with 0.03% Tacrolimus Eyedrops
Autologous Serum Eye Drops
For severe cases that do not respond adequately to standard drops, eye drops made from the patient’s own blood serum offer an additional option. These serum drops contain growth factors, vitamins, and other components naturally present in tears that artificial formulations lack. A retrospective study of patients with severe chronic ocular GVHD found that six months of serum drop use led to significant improvements in corneal staining and symptom scores, along with reduced dependence on artificial tears. Visual acuity improved as well, reaching statistical significance in at least one eye.16PubMed. Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study The downside is that producing these drops requires regular blood draws and specialized processing, making them less convenient and more expensive than standard therapies.
Scleral Contact Lenses
Scleral lenses, which are large rigid lenses that vault over the entire cornea and rest on the white of the eye, have become an increasingly important tool for ocular GVHD. They trap a layer of saline against the cornea, bathing it continuously in moisture and protecting it from the air and from blinking friction. In a study of mini-scleral lenses in chronic ocular GVHD patients, median visual acuity improved from 20/40 with glasses to 20/25 with the lenses. Symptom scores dropped dramatically, with median OSDI scores falling from 73 to 27, and corneal staining improved in most patients.17PubMed Central. Visual and ocular surface benefits of mini-scleral contact lenses in patients with chronic ocular graft-versus-host disease (GvHD) For patients whose quality of life has been heavily impacted, scleral lenses can be transformative, though they require careful fitting and daily cleaning routines of their own.
Systemic Medications
Because ocular GVHD is ultimately driven by a body-wide immune response, systemic medications sometimes help where topical treatments cannot. Belumosudil, an oral medication that targets a specific immune signaling pathway, has shown promise in patients with steroid-resistant chronic GVHD. In one evaluation, about 54% of patients showed improvement in their ocular GVHD severity score after six months on the drug, and roughly 65% reported symptomatic improvement. Objective measures including corneal staining, tear break-up time, and Schirmer test values all improved modestly.18PubMed. Systemic Treatment With the ROCK2 Inhibitor Belumosudil in Ocular Chronic Graft-Versus-Host Disease Systemic treatments carry their own side-effect profiles and are typically reserved for patients with GVHD affecting multiple organs, not the eyes alone.
When Things Get Serious: Corneal Ulcers and Perforation
The chronically inflamed, poorly lubricated cornea in ocular GVHD is vulnerable to ulceration. A review of corneal ulcers in these patients found that about two-thirds were infectious and one-third were non-infectious (sterile melts caused by inflammation alone). Infectious ulcers fared considerably worse, with treatment failure occurring in over half of cases compared to about 20% of non-infectious ulcers.19PubMed Central. Infectious and Non-infectious Corneal Ulcers in Ocular Graft-Versus-Host Disease: Epidemiology, Clinical Characteristics and Outcomes Immunosuppression from transplant medications compounds the problem by making infections harder to clear.
In the most extreme scenario, the cornea can perforate. A case report described combining a corneal transplant with an amniotic membrane wrap to achieve structural stability and useful vision even in this hostile inflammatory setting. The amniotic membrane helped calm the inflammation and supported tissue healing, potentially reducing rejection risk compared to a standard corneal transplant alone.20PubMed Central. Amniotic Membrane-Assisted Corneal Transplantation in Ocular Perforation Due to GVHD: A Case Report Corneal perforation remains rare, but it illustrates why aggressive management of dry eye and surface inflammation matters: the goal is to prevent this kind of catastrophic endpoint.
Children With Ocular GVHD
Pediatric patients develop ocular GVHD at rates comparable to adults, but detecting it is harder. In a study of children after stem cell transplant, about 42% developed new dry eye disease, yet only 27% of those children actually complained of symptoms.21Scientific Reports. Pediatric chronic graft-versus-host disease-related dry eye disease and the diagnostic association of potential clinical findings Young children in particular may not have the vocabulary to describe eye discomfort, or they may adapt to progressively worsening vision without realizing it is abnormal. In that same study, four children developed ocular GVHD as the first sign of systemic GVHD, meaning the eye findings preceded any other organ involvement.
A separate evaluation of pediatric patients found that chronic ocular GVHD developed in about 64% of children studied. The most commonly reported symptoms were burning, stinging, foreign body sensation, and light sensitivity. About 13% had severe dry eye requiring topical cyclosporine on top of artificial tears, with mixed results: some improved while others had to discontinue due to side effects.22PubMed Central. Ocular Findings of Pediatric Dry Eye Related to Graft-Versus-Host Disease The evidence argues strongly for routine eye exams in all children after transplant, regardless of whether they voice complaints.
The Daily Burden
Living with ocular GVHD means more than occasional eye drops. Treatment typically involves a combination of lubricants, anti-inflammatory drops, lid hygiene, warm compresses, and sometimes serum drops or scleral lenses, all performed on a schedule throughout the day. In a study assessing the clinical burden, 39% of patients with ocular GVHD reported spending an hour or more each day on their dry eye treatment alone.23PubMed Central. Clinical burden of dry eye disease in patients with ocular graft versus host disease The financial cost is real too: the median annual out-of-pocket expense for dry eye treatments in that study was about $900, though the average was pulled much higher (over $2,600) by patients with severe disease who needed expensive therapies like serum drops or specialty lenses.
This daily treatment load lands on people who are already managing a complex post-transplant medication regimen and dealing with the physical and emotional toll of a serious illness. The psychological impact is not trivial. Difficulty reading, driving, and working at a computer can undermine independence and employment at a time when patients are trying to rebuild their lives after cancer treatment. Among the various manifestations of chronic GVHD, the eyes are often the site patients find most distressing precisely because vision loss is so directly tied to daily functioning and autonomy.
What Regular Screening Looks Like
Most transplant centers now recommend baseline eye exams before or shortly after transplant, with follow-up visits every three to six months for the first two years and annually thereafter. The exam typically includes a Schirmer test (a small strip of paper placed under the lower eyelid to measure tear production), corneal staining with fluorescein dye to check for surface damage, and an assessment of meibomian gland function. These tests are quick and painless, but they need to happen regularly because ocular GVHD can worsen between visits without the patient noticing a dramatic change.
Because ocular GVHD can appear before systemic GVHD is diagnosed, eye findings sometimes serve as an early warning. Transplant teams increasingly recognize that an ophthalmologist flagging new dry eye or corneal changes can prompt systemic evaluation that catches GVHD in other organs sooner than it would otherwise be detected. This bidirectional communication between eye doctors and transplant physicians is one of the more practical improvements in GVHD care over the past decade.